Drugs / Thymoglobulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00065260 | Nov 2003 → Dec 2010 | aplastic anemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Thymoglobulin | “This study will enroll patients who are either refractory to h-ATG (continued severe pancytopenia) or who have only modest improvement in blood counts (weak hematologic...” NCT00065260 ↗ |
| Known as | r-ATG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00065260 ↗ |
| Modality | Protein / enzyme biologic | “rabbit anti-thymocyte globulin (r-ATG)” NCT00065260 ↗ |